Do the trials with interferon alfa for patients with HBV or HCV cirrhosis exhibit a favorable result due to the antiviral properties of interferon, or is interferon exhibiting anti-oncogenic potential?, and is HCC cytokine and hormone sensitive (view ongoing trials with somatostatine analogues versus HCC)? (hence, if we treat alcoholic cirrhosis patients with interferon could we have a favorable response?).